Cargando…
Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod
Each year, despite optimal use of recommended acute and secondary prevention therapies, 4%–5% of patients with acute coronary syndrome (ACS) experience relapse of ACS or other cardiovascular events including stroke, heart failure, or sudden cardiac death after the index ACS. The sudden atherosclerot...
Autores principales: | Kragholm, Kristian, Newby, Laura Kristin, Melloni, Chiara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532348/ https://www.ncbi.nlm.nih.gov/pubmed/26273189 http://dx.doi.org/10.2147/DDDT.S69546 |
Ejemplares similares
-
Losmapimod: A Novel Clinical Drug to Overcome Gefitinib-Resistance
por: Nishimura, Yukio
Publicado: (2018) -
Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis
por: Gipson, Debbie S., et al.
Publicado: (2020) -
Identification of a clinical compound losmapimod that blocks Lassa virus entry
por: Zhang, Xiaoyu, et al.
Publicado: (2019) -
Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization
por: Yeung, Yiu To, et al.
Publicado: (2018) -
Losmapimod Protected Epileptic Rats From Hippocampal Neuron Damage Through Inhibition of the MAPK Pathway
por: Li, Min, et al.
Publicado: (2019)